Drug Profile
Vimirogant - AbbVie/Vitae Pharmaceuticals
Alternative Names: AGN-242428; VTP43742Latest Information Update: 12 Apr 2022
Price :
$50
*
At a glance
- Originator Vitae Pharmaceuticals
- Developer AbbVie; Allergan
- Class Antipsoriatics; Pyridines; Pyrroles; Small molecules
- Mechanism of Action Immunosuppressants; Nuclear receptor subfamily 1 group F member 3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Dry eyes
- Discontinued Autoimmune disorders; Multiple sclerosis; Plaque psoriasis; Psoriasis
Most Recent Events
- 18 Mar 2022 Allergan completes a phase II trial in Dry eyes in USA (Topical) (NCT04030962)
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 04 Mar 2020 Phase-II clinical trials in Dry eyes in USA (Topical) in March 2020 (NCT04030962)